A panelist discusses how bleeding risk assessment depends on platelet count levels (highest risk below 20,000), requiring careful medication history review to avoid drugs that impair platelet function ...

A panelist discusses how ITP diagnosis remains one of exclusion requiring thorough testing to rule out other causes of thrombocytopenia, followed by patient education about autoimmune diseases and ...

"Care of the elderly has become its own science and is very different in virtually everything than is the care of a typical middle-aged adult. This is important for ITP." — James Bussel, MD Reflecting ...

DEAR DR. ROACH: What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and after lab results showed a low blood platelet count, I ...

Several areas of discordance were observed, including contributing causes for delay in diagnosis, with patients perceiving extended wait times as a significant contributing factor. Patients were ...

Dear Dr. Roach: What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and after lab results showed a low blood platelet count, I ...

The elevated risk of developing CVD in the ITP cohort (adjusted incidence rate ratio [IRR], 1.38) remained even after a sensitivity analysis which included only incident cases of ITP. HealthDay News — ...

Credit: Getty Images. The patient, who was initially diagnosed with Gaucher disease type 1 during her first pregnancy 20 years prior, presented with bleeding, hematomas, and thrombocytopenia, in ...

Sept. 27, 2004 — Successful eradication of Helicobacter pylori infection results in significant platelet recovery in 56% of patients with chronic idiopathic thrombocytopenic purpura (ITP), according ...

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or ...

STOCKHOLM, March 12, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announces that the first patient has been dosed with avatrombopag, a thrombopoietin receptor ...